Weight‐Reduction and Safety Profile of Once‐Weekly Non‐Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real‐World Retrospective Study

ABSTRACT Background and Aims Semaglutide, a once‐weekly injectable glucagon‐like peptide, showed double‐digit weight reduction with an acceptable safety profile in clinical trials and real‐world studies. The efficacy and safety of non‐comparable biotherapeutic (NCB) semaglutide are not adequately re...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Md Rakibul Hasan, Kishore Kumar Shil, Md Shahed‐Morshed
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-01-01
coleção:	Health Science Reports
Assuntos:	non‐comparable biotherapeutic semaglutide Obesity Semaglutide Weight loss
Acesso em linha:	https://doi.org/10.1002/hsr2.71745
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!